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Background: Artesunate + sulphadoxine-pyrimethamine (AS + SP) is recommended throughout India as the first-line
treatment for uncomplicated falciparum malaria. Due to the presence of several eco-epidemiological zones of malaria
and variable drug pressure, it is necessary to evaluate the efficacy of this combination in different regions of India. The
objective of this study was to use clinical and molecular methods to monitor the efficacy of AS + SP in three diverse
sites.
Methods: The study was undertaken in three high endemic sites of central and eastern India. Patients with
uncomplicated falciparum malaria were enrolled and followed for 28 days. Molecular genotyping was conducted for
merozoite surface protein (msp1 and msp2) to differentiate between re-infection and recrudescence and for the dhfr
and dhps genes to monitor antifolate drug resistance.
Results: In all, 149 patients were enrolled at the three sites. The crude cure rates were 95.9%, 100%, and 100% in
Ranchi, Keonjhar, and West Garo Hills respectively. PCR-corrected cure rates were 100% at all sites. In dhfr, 27% of
isolates had triple mutations, while 46% isolates were double-mutants. The most prevalent mutation was S108N
followed by C59R. 164 L mutation was observed in 43/126 (34%) isolates. In dhps, most (76%) of the isolates were
wild-type. Only 2.5% (2/80) isolates showed double mutation. dhfr-dhps two locus mutation were observed in 16%
(13/80) isolates. Parasite clearance time was not related with antifolate mutations.
Conclusions: AS + SP combination therapy remained effective against falciparum malaria despite common mutations
promoting resistance to antifolate drugs. Although the prevalence of double and triple mutations in dhfr was high, the
prevalence of dhfr-dhps two locus mutations were low. Even isolates with dhfr triple and dhfr-dhps two locus
mutations achieved adequate clinical and parasitological response.
Keywords: Artesunate + sulphadoxine-pyrimethamine, Plasmodium falciparum, Dihydrofolate reductase,
Dihydropteroate synthetase, Falciparum malariaBackground
Anti-malarial drug resistance has been a major obstacle in
the fight against malaria and has been documented globally
in Plasmodium falciparum. In India, chloroquine (CQ)
resistance was first reported in Assam in 1973 [1] and
thereafter several reports of resistance were confirmed
from all over India [2-6]. Sulphadoxine-pyrimethamine* Correspondence: srivastavaprakriti@rediffmail.com
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reproduction in any medium, provided the or(SP) became the alternative to CQ for the treatment and
control of uncomplicated malaria. It was effective,
affordable and easy to comply with, but in course of time
the accumulations of mutations in parasite genes coding
for two enzymes dihydrofolate reductase (DHFR) and
dihydropteroate synthetase (DHPS) led to SP resistance in
certain sites, mostly in north-east India [7]. In 2001, the
World Health Organization (WHO) recommended the
use of artemisinin based combinations therapy (ACT), in
which a long-acting partner is added to artemisinin to make
it more effective, as first-line treatment for uncomplicatedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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countries adopted ACT. In 2005, AS + SP was introduced
in the National Drug Policy for malaria in India in selected
areas, and in 2010 it became the universal first-line drug for
falciparum malaria. With the replacement of monotherapy
by ACT, it is important to understand the relationship be-
tween molecular markers, parasite resistance and treatment
failure.
Several challenges exist in understanding this correlation
since molecular markers for artemisinin resistance have
not been established. These markers however, are well
established for SP. Sulphadoxine acts as competitive
inhibitor in folate biosynthetic pathway of parasite by
inhibiting the enzyme DHPS [9]. Pyrimethamine inhibits
the DHFR enzyme of P. falciparum, also a component of
the folate-biosynthetic pathway. Mutations in some of the
key amino acids of this enzyme lead to reduced binding
affinity with the drug, leading to resistance [10]. In the
AS + SP combination, AS rapidly clears parasitaemia.
SP kills the remaining parasites, since it has a long half-life
in blood. Thus, for clinical and parasitological treatment
outcomes, early treatment failure (ETF) is more likely
associated with AS failure and late treatment failure (LTF)
with SP failure. The determination of parasite density on
day 0 and the proportion of patients positive on day 3
could thus be a key indicator for the in vivo susceptibility
of artemisinin [11].
Since pre-existing resistance to SP exists in India,
especially along the border with Myanmar where reduced
artemisinin sensitivity has been reported, it is important
to monitor both in vivo and in vitro responses to this
combination. Therefore, the objective of the present study
was to: 1) measure the in vivo efficacy of AS + SP including
treatment failure and parasite clearance; 2) examine
molecular markers for SP to understand the mutation
pattern; and, 3) correlate molecular marker results with
clinical outcomes.
Methods
This was a single arm prospective study carried out from
2007 to 2010 (Aug-Oct 2007 in Ranchi, Sep-Nov 2007
in Keonjhar and June-Oct 2010 in West Garo Hills) to
evaluate the parasitological and clinical response to
directly observed treatment for uncomplicated falciparum
malaria [12].
Study sites
The study was carried out at three sites (Figure 1). Ranchi
(Jharkhand): Jharkhand contributes to 7% of the two
million reported cases of malaria in India. The study
district Ranchi is the capital of Jharkhand and is highly
endemic for malaria with an average elevation 629 m
above sea level. Ranchi has a hilly topography with
dense tropical forests. The main vector of malaria inRanchi is Anopheles fluviatilis and predominant tribes
living there are Oram and Munda. Keonjhar (Odisha).
In India, Odisha state contributes to 40% of reported P.
falciparum cases. The climate of the study district is hot
in summer with high humidity. The district is covered
by 30% of forest of the total geographical area. Main
vector of malaria is An. fluviatilis. There are 16 tribal
populations in Keonjhar with the Oram and Munda as
predominant tribes. West Garo Hills (Meghalaya): P.
falciparum-related deaths are routinely reported annually
from West Garo Hills district, located at the western most
part of Meghalaya. There is heavy rainfall during May to
September with a seasonal peak from May to July. The
main vector of malaria is Anopheles minimus [13]. The
Khasis are the largest group of tribes, followed by the
Garos. Partial data from this study site was already
published [14]. However detailed clinical and molecular
data are presented in this paper.
Enrolment
All patients reporting to a local clinic with complaint of
fever were examined for presence of parasites in the
blood smear. The demographic information (age, gender,
body temperature, body weight) were recorded. Peripheral
smear was examined and those positive for P. falciparum
were enrolled. Informed consent was obtained and case
record form was completed for each patient.
Inclusion and exclusion
Patients aged above six months with mono-infection with
P. falciparum, with parasitaemia of 1,000 to 100,000/μl,
axillary temperature ≥37.5°C or history of fever during
previous 24 hours and agreeing to follow-up visits, were
included in study. Patients with presence of one or more
general danger signs or any sign of severe malaria, presence
of mixed infection, severe malnutrition, febrile conditions
caused by diseases other than malaria, contra-indications
related to anti-malarial drugs used, and pregnancy, were
excluded from this study.
Treatment
AS was given at a target dose of 4 mg/kg daily for three
days; SP were given as a single dose equivalent to 25/
1.25 mg/kg (IPCA Laboratories Ltd, Mumbai). Agewise
dosing was followed rather than weightwise [15]. Patients
were observed for 30 min and if they vomited during this
period, the first dose was repeated.
Follow-up
Clinical (temperature, vital symptoms, physical parameters)
and parasitological (thick and thin slide) assessment were
done on days 0, 1, 2, 3 and 7 and then weekly until day 28.
However, patients were advised to return on any day
during follow-up if symptoms existed. For defaulters,
Figure 1 Selected study sites for AS + SP therapeutic efficacy studies, Keonjhar (Odisha), Ranchi (Jharkhand) and West Garo Hills
(Meghalaya) and total mutations in dhfr and dhps gene, 2007 and 2010. Abbreviations: SM, single mutation, DM, double mutation, TM, triple
mutation, QM, quadruple mutation.
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or place of work. Patients were advised to use personal
protection measures to prevent re-infection.
Microscopy
Thick and thin blood smears were examined for presence
of parasite. Thick blood films were stained with Giemsa
and parasite density determined by counting parasites
against 200 white blood cells (WBC) and assuming WBC
count to be 8,000/μl. The parasite clearance time (PCT)
was determined based on a daily blood smear as per the
WHO protocol for therapeutic efficacy studies. Finger
prick blood samples were collected on Whatman 3 mm
filter papers on admission and on the day of re-appearance
of parasites after complete anti-malarial treatment during
follow-up and unscheduled day.
Molecular analysis
DNA was isolated from dried blood spot using DNA isola-
tion kit according to manufacturer’s instructions (Qiagen,
Valencia, CA, USA). To distinguish re-infection and re-
crudescence, parasite genotyping for polymorphic loci, mer-
ozoite surface proteins (msp1 and msp2) were conducted
according to the published method [16]. Mutation specific
PCR were conducted to amplify dhfr and dhps gene
according to method described earlier [17]. The dhfr
fragment of 720 base pair was amplified first and then
mutation specific PCR were carried out for codon 16,51, 59, 108 and 164. In dhps, primary PCR were carried
out to obtain a PCR product of 1.33 kb. Nested PCR were
performed using two flanking and seven mutation-specific
primers to detect point mutations at codon 436, 437, 540,
581 and 613. Molecular markers were analyzed in all D0
samples to get data of the baseline antifolate mutations
regardless of follow-up and clinical outcomes.
Classification of outcomes
Treatment outcomes were classified as early treatment fail-
ure (ETF), late clinical failure (LCF), late parasitological
failure (LPF), adequate clinical and parasitological response
(ACPR) on the basis of an assessment of the parasitological
and clinical outcome of anti-malarial treatment according
to the latest WHO guidelines [18].
Data analysis
Computer-based applications prepared by WHO for data
management and analysis were used (software package
developed by WHO’s Global Malaria Programme for
evaluating therapeutic efficacy). Data were entered into
WHO software for Kaplan-Meier analysis for calculating
cure rates. Results were expressed as the cumulative success
rate and the proportion of adequate clinical and parasito-
logical response (ACPR) before and after adjustment by
PCR. The primary endpoint of the study was the per
protocol (PP)-PCR corrected cure rate. The secondary
endpoints included the parasite clearance time (PCT),
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on day 28, and proportion of patients with ETF, LTF and
LPF. The sum of dhfr and dhps mutations were defined as
the total number of antifolate mutations. Fisher’s exact test
was used to find association between antifolate mutations
and parasite clearance.
Sample size
The study was designed according to WHO therapeutic
efficacy protocol which recommends a minimum of 50
patients in a site for appropriate precision (5%) to detect
an unknown treatment failure rate with 95% confidence.
We aimed to recruit approximately 70 patients in each
site in case of loss to follow-up.
Ethics
The study was approved by Institutional Ethical Committee
of National Institute of Malaria Research (NIMR). Patients
were included in the study only if they or their parents
or guardians gave informed consent. All information on
patients was kept confidential.
Results
In vivo efficacy of AS + SP
A total of 149 patients were enrolled during 2007–2010
at three sites. Most patients were below 15 years of ageTable 1 Demographic and clinical characteristics of
patients enrolled for AS + SP therapeutic efficacy studies,






Hills (N = 25)
n % n % n %
Gender
Male 31 44 22 42 15 60
Female 40 56 31 58 10 40
Age groups
<5 31 44 12 22 7 28
5-14 25 35 19 36 14 56
≥15 15 21 22 42 4 16
Parasitaemia/μL on day 0
<5000 27 38 8 15 12 48
5000-50000 29 41 34 64 10 40
>50000 15 21 11 21 3 12
Parasite clearance time
<24 hours 46 65 48 90 22 98
24-48 23 32 5 10 3 2
>48 2 3
Fever on day 0
(auxiliary temperature) ≥37.5°C
71 100 45 85 8 32
≤37.5°C 0 0 8 15 17 68
Abbreviations: N, total number of patients enrolled; n, out of total enrolled.with fever on enrolment and parasitaemia between 5,000-
50,000/μl blood (Table 1). Out of 149 patients, four (3%)
were lost to follow-up and five (3%) were withdrawals
(four protocol violations in inclusion and one with
Plasmodium vivax infection). There were two treatment
failures on day 26 and 27 from Ranchi. No clinical or
parasitological failures were reported from other sites
(Figure 2).
The parasite clearance was rapid at all sites and complete
clearance of parasitaemia within 48 hours of administration
of drug were observed in 97% (69/71) in Keonjhar, 100%
(53/53) in Ranchi and (25/25) West Garo Hills (Table 1).
Proportion of patients with gametocytes at enrolment
was 13% (9/71), 30% (16/53) and 12% (3/25) respectively
in Keonjhar, Ranchi and West Garo Hills. Gametocytes
were detected in only one patient on day 28 from West
Garo Hills.
Out of two cases of treatment failure, one had tem-
perature 38.5°C and 9% of day 0 parasitaemia on day 26
and classed as LCF. Another was classed as LPF as he
had temperature 36.8°C and 21% of day 0 parasitaemia
on day 28. Molecular genotyping for msp1 and msp2 of
failure samples indicate multiple infections and classified
as a re-infection. PP-PCR-uncorrected cure rates were
95.9% (95% CI: 86, 99.5), 100% (95% CI: 94.6, 100), and
100% (95% CI: 86.3, 100) respectively at Ranchi, Keonjhar
and West Garo Hills. After PCR-correction, cure rates
were 100% at all sites.
Molecular analysis of dhfr and dhps gene
All isolates were analysed for dhfr mutations encoding
pyrimethamine resistance and dhps mutations associated
with sulphadoxine resistance (Table 2). In dhfr, 136 (91%)
isolates were successfully amplified. The S108N mutation
was the most common and found in all amplified samples.
Seventy-one percent of the samples were mutant at amino
acid position C59R; I164L mutation was observed in 34%
of isolates. In dhfr, double mutants (S108N + C59R or
I164L) were the most common in all three sites: Ranchi
(47%, n = 22/47) and Keonjhar (49%, n = 27/55) and West
Garo Hills (17%, n = 3/18). Other than double mutations,
the triple mutant C59R + S108N + I164L were also
detected in all sites but its prevalence was highest in West
Garo Hills (83%, n = 15/18) followed by Ranchi (28%,
n = 13/47) and Keonjhar (18%, n = 10/55). Single mutation
S108N were observed in Keonjhar (33%, n = 18/55) and
Ranchi (26%, n = 12/47) only.
In dhps, out of 149 collected isolates, 88 (59%) were
successfully amplified. Mutations were found in 19%
(n = 17/88) of the samples. A single mutation at amino
acid position 581 was observed in 8% (n = 7/88) and at
amino acid position 540 was present in 6% (n = 5/88)
of isolates. Double mutations at position 540 and 581
were observed in 1% (n = 1/88) of isolates.
Figure 2 Flow chart of patients enrolled for AS + SP treatment at Keonjhar (Odisha), Ranchi (Jharkhand) and West Garo Hills
(Meghalaya), India, 2007 and 2010. Abbreviations: Pv, Plasmodium vivax; LTF, late treatment failure.
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quadruple mutations were present in 7% (6/80) of isolates
and triple mutations in 27% (22/80). The majority 42%
(34/80) of isolates had double mutations, while 22%
(18/80) of isolates had single mutations. Notably, none of
the isolates had quintuple mutations. Twenty-five percent
(20/80) of isolates with any of these mutations cleared para-
sitaemia after 24 hours of introduction of drug (Table 3).
Ten different haplotypes were detected, of which, two were
present in each site, two in Keonjhar and Ranchi, one (10%)
in Ranchi and West Garo Hills, while two (20%) in RanchiTable 2 Prevalence of point mutation in dhfr and dhps
gene in day 0 samples of patients enrolled for AS + SP
therapeutic efficacy studies, central and eastern India,
2007 and 2010
Keonjhar (n = 71) Ranchi (n = 53) WGH (n = 25)
Genes Codons n M %M n M % M n M %M
dhfr C59R 59 38 64 53 36 68 18 18 100
S108N 60 60 100 50 50 100 19 19 100
I164L 60 20 33 52 18 35 14 5 36
dhps K540E 28 11 39 28 4 12 10 6 60
A581G 28 8 28 28 5 14 15 0 0
Abbreviations: WGH, West Garo Hills; n, number; M, mutant.alone and three (30%) in Keonjhar alone. Maximum
numbers of haplotype were seen in Keonjhar (Table 4).Correlation of molecular markers with clinical outcomes
Among the two treatment failures, molecular genotyping
of isolates of day 0 and failure day revealed that in both
cases isolates had double mutations in dhfr (108 + 59) in
day 0, while failure day isolates had an additional mutation
in dhps, one with 540, the other with 581 mutations.
Complete clearance of parasitaemia in less than 24 hours
were observed in 78% (116/149) of patients, while 21%
(31/149) cleared in between 24 to 48 hours. Only 1%
(2/149) cleared in more than 48 hours. There was no
statistically significant association between parasite clear-
ance time and increased mutations in dhfr and dhps
(P value = 1.24). However, among the isolates that cleared
parasitaemia in more than 48 hours, all of them carried
108 + 59 mutations. Isolates with 108 + 164 + 540 cleared
parasites between 24 to 48 hours.Discussion
AS + SP remained efficacious for the treatment of P.
falciparum across diverse sites in central and eastern
India. Molecular genotyping of dhfr and dhps genes
indicate the dominance of isolates with dhfr double
Table 3 Antifolate (dhfr and dhps) mutations, clinical
outcome and parasite clearance time of patients enrolled
for AS + SP treatment, central and eastern India, 2007
and 2010
Type of mutation n(80) PCT >24 h Outcome
n %
Quadruple 6 2 34 ACPR
Triple 22 6 27 ACPR
Double 34 7 20 ACPR
Single 18 5 28 ACPR
Abbreviations: ACPR, adequate clinical and parasitological response.
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development of antifolate resistance.
Despite the presence of mutations in dhfr and dhps gene,
AS + SP treatment remained successful. This may be due
to several reasons: first, the action of artemisinin in com-
bination therapy, which kills parasites rapidly and reduces
SP drug pressure on the parasite, preserving the latter’s
efficacy; second, the rarity of dhfr-dhps quintuple mutations,
which are virtually synonymous with SP treatment failure,
in the population studied. However, it is likely that in the
course of time such haplotypes may develop and spread
in the face of sustained selection pressure; third, host
immunity contributes to treatment efficacy and the study
population was dominated by persons of tribal ethnicity
living in highly endemic areas, who would have high
immunity. The findings of this study were similar to those
of Mishra et al. who reported AS + SP combination as a
safe and effective treatment for uncomplicated falciparum
malaria in India during 2009–2010 across 22 sites [14].
This study contributes ‘baseline’ data on antifolateTable 4 Prevalence of dhfr/dhps haplotype in day 0 samples o
studies, central and eastern India, 2007 and 2010













Abbreviations: WGH, West Garo Hills.
Mutated amino acids are in bold.resistance as the bulk of samples were collected in 2007
prior to the widespread scale-up of AS + SP.
SP is extensively used, widely available, inexpensive,
and slowly eliminated from the body. These factors
have promoted the emergence and spread of SP-resistant
parasites. Mutations in dhfr gene are related to pyrimeth-
amine resistance and develop stepwise, starting with the
mutation at codon S108N (Ser-Asn), followed by subse-
quent mutations at codon 59 (Cys-Arg), 51 (Asn-Ile) and
164 (Ile-Leu). In India, the most common dhfr mutation is
S108N, followed by C59R, and N51I [17,19,20]. The
results of this study showed a similar pattern with the
exception of an absence of mutation in codon N51I. It
was observed the I164L mutation associated with high
levels of pyrimethamine resistance [21]. Previous studies
in Assam, in north-east India and Odisha in eastern India,
documented the dhfr triple mutant Asn108 + Ile51 +Arg59
associated with pyrimethamine resistance [17]. These com-
binations of mutations were not detected in the present
study sites which are in nearby states. The dhfr double
mutations (S108N + C59R) were the most prevalent here
similar to other reported results [22]. This study did not
detect any quadruple mutations in dhfr such as those
reported from the Andaman and Nicobar Islands by
Ahmed [20] and Das et al. [23]. The success rate of dhps
gene amplification was low compared to amplification of
the dhfr gene; however, isolates where it was successfully
amplified were wild type. Other authors have also reported
the dominance of wild type dhps genotype in India
[14,17,22,]. The prevalence of dhps single mutation (K540E
or A581G) and double mutations (540 + 580) were low and
triple mutant dhps alleles were not detected though reports
exist, again, from the Andaman and Nicobar Islands [24].f patients enrolled for AS + SP therapeutic efficacy
jhar Ranchi WGH
42) (n = 32) (n = 6)
% n % n %
- 2 6 - -
4 - - 2 33
14 4 13 - -
10 2 6 3 50
2 - - - -
- 2 6 - -
29 13 41 1 17
10 - - - -
10 - - - -
21 9 28 - -
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sive, with some haplotypes common among Jharkhand,
Odisha and West Garo Hills, while others were site
specific. The highest number of haplotypes was present in
Odisha, which contributes the highest proportion of the
reported malaria burden in the country. Thus, high trans-
mission generates higher diversity. In low-transmission
areas in contrast, self-recombination leads to greater
fixation of haplotypes. Ahmed et al. [17] described similar
regional differences where more diverse genotypes were
seen in the higher transmission states of Assam and
Odisha. In addition to transmission, drug pressure varies
across states. In low-transmission settings a greater pro-
portion of infections are likely to be symptomatic, and
since these areas also tend to be better developed, more
cases will have access to care leading to high selection
pressure. Anderson et al. [25] suggest resistance to SP
appears to arise de novo much less frequently but spreads
rapidly since gametocyte production is stimulated by this
drug. High-level pyrimethamine-resistant alleles have
emerged in independent foci from which they have rapidly
spread to the nearby areas. In contrast, Vinayak et al. [26]
found single origin for dhfr-resistant alleles in the
Thai-Cambodia region, while dhps-resistant alleles had
multiple origins. Lumb et al. [27] reported several unique
haplotypes among mutant dhps alleles and concluded that
the dhps alleles in India have evolved from multiple
genetic backgrounds.
Delayed parasite clearance time is the most important
signal for artemisinin resistance [28]. The parasite clearance
was rapid at all sites in this study. This rapid clearance
of parasitaemia is suggestive of continued artemisinin
effectiveness in India though better inference could be
made with precise data on parasite clearance rates. No
statistically significant association between parasite clear-
ance time and increased mutations in dhfr and dhps was
observed, which was not surprising if the artemisinin
component drives clearance. Since the treatment efficacy
was high, it was not possible to correlate molecular results
with subsequent treatment failure.
The present study had several limitations. Foremost
was a follow-up of only 28 days. As the partner drug
(SP) has a long half-life, extended follow-up for 42 days
could have detected potential late treatment failures
emerging with the elimination of residual drug levels.
Second, only 25 patents were enrolled in West Garo
Hills because enough eligible patients were not found at
the recruitment site during the transmission season.
Third, the lack of treatment failures restricted the ability
to determine the relationship between molecular markers
and AS + SP failure. Fourth, the parasite clearance time
(PCT) was determined based on a daily blood smear.
Finally, while three sites provided some geographic cover-
age, the results may not be generalizable across India giventhe size of the country and diversity of malaria ecotypes.
The diversity of findings in dhfr and dhps mutations alone
suggests the need for routine monitoring especially in
locations with a high prevalence of markers associated
with anti-malarial drug resistance. One potential solution,
which would minimize the need for expensive in vivo
trials, is the targeting of such studies using molecular
surveillance [29].
Conclusion
This study suggests that AS + SP remains effective for the
treatment of uncomplicated falciparum malaria in central
and eastern India despite the presence of mutations in the
dhfr and dhps genes. Regular monitoring of the efficacy of
AS + SP will help safeguard this combination treatment.
Molecular studies of dhfr and dhps would be helpful in
detecting increased resistance against the partner drug SP
and potentially targeting study sites to where treatment
failure is likely to emerge.
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